Totally Agree with All you say @Uboy
FDA outcome pivotal IMHO
- Forums
- ASX - By Stock
- PER
- Sarepta gene therapy study missed key target in Duchennes
Sarepta gene therapy study missed key target in Duchennes, page-333
-
-
- There are more pages in this discussion • 81 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add PER (ASX) to my watchlist
|
|||||
Last
8.5¢ |
Change
-0.002(2.30%) |
Mkt cap ! $76.63M |
Open | High | Low | Value | Volume |
8.7¢ | 8.7¢ | 8.5¢ | $12.66K | 146.8K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
3 | 197135 | 8.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
8.7¢ | 329525 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
3 | 197135 | 0.085 |
3 | 457608 | 0.084 |
3 | 212500 | 0.083 |
1 | 21000 | 0.081 |
2 | 106250 | 0.080 |
Price($) | Vol. | No. |
---|---|---|
0.087 | 329525 | 1 |
0.088 | 457142 | 2 |
0.089 | 135000 | 2 |
0.090 | 294374 | 4 |
0.092 | 550000 | 2 |
Last trade - 10.14am 02/09/2024 (20 minute delay) ? |
Featured News
PER (ASX) Chart |
The Watchlist
CCO
THE CALMER CO INTERNATIONAL LIMITED
Anthony Noble, MD & CEO
Anthony Noble
MD & CEO
Previous Video
Next Video
SPONSORED BY The Market Online